ROUNDTABLE: Bioconjugates – From Targets to Therapeutics

This podcast features:
Alan C. Rigby, PhD, Vice President Research, ImClone Systems

Dr James R. Prudent, President and Chief Executive Officer, Centrose
Jason C. Brady, PhD, Director, Business Development, Conjugates and Cytotoxics, Lonza
John Burt, Chief Executive Officer, PolyTherics
Trishul P. Shah, Business Development Manager, PolyPeptide Group
John M. Lambert, EVP & CSO, ImmunoGen, Inc



This podcast was recorded at the 2013 BioProcess Theater which took place at the 2013 BIO International Convention, April 22-25, 2013. The BioProcess Theater, a 50-seat amphitheater located on the exhibition floor at the heart of the BioProcess Zone, provided attendees with daily, complimentary opportunities to listen, learn, and interact with leading experts as they presented, discussed and debated the latest business and scientific trends impacting the development and manufacture of biotherapeutics.

The 2013 BioProcess Theater consisted of five main presentation tracks: Biosimilars, Single-Use Processing, Cell Therapy, Antibody/Non-Antibody Manufacturing, and Vaccine Manufacturing.

If you would like more information on these presentations, please email us:

Leave a Reply